FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Vural Ozdemir

Research Profile

Occupations

Chemicals & Drugs

Disorders

Physiology

Concepts & Ideas

Risk Factors

Co-author Network

Publications

TOP 3
Béatrice Godard; Vural Ozdemir; Marilyn Fortin; Nathalie Egalité
Ethnocultural community leaders' views and perceptions on biobanks and population specific genomic research: a qualitative research study.
Vural Ozdemir; Bartha Maria Knoppers
One size does not fit all: toward "upstream ethics"?
Vural Ozdemir
What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real-time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Vural Ozdemir (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Béatrice Godard; Vural Ozdemir; Marilyn Fortin; Nathalie Egalité
Ethnocultural community leaders' views and perceptions on biobanks and population specific genomic research: a qualitative research study.
Public understanding of science (Bristol, England) 2010;19(4):469-85.
2010: Vural Ozdemir; Bartha Maria Knoppers
One size does not fit all: toward "upstream ethics"?
The American journal of bioethics : AJOB 2010;10(6):42-4.
2009: Vural Ozdemir
What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real-time assessment of social risks in multiply marginalized populations can prevent IRB mission creep, ethical inflation or underestimation of risks.
The American journal of bioethics : AJOB 2009;9(11):65-8.
2009: Eleni Aklillu; Sara Karlsson; Olof O Zachrisson; Vural Ozdemir; Hans Agren
Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression.
Pharmacogenetics and genomics 2009;19(4):267-75.
2009: Vural Ozdemir; Guilherme Suarez-Kurtz; Raphaëlle Stenne; Andrew A Somogyi; Toshiyuki Someya; S Oguz Kayaalp; Eugene Kolker
Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society.
Omics : a journal of integrative biology 2009;13(1):43-61.
2009: Vural Ozdemir; Arno G Motulsky; Eugene Kolker; Béatrice Godard
Genome-environment interactions and prospective technology assessment: evolution from pharmacogenomics to nutrigenomics and ecogenomics.
Omics : a journal of integrative biology 2009;13(1):1-6.
2008: Louise Lévesque; Vural Ozdemir; Béatrice Godard
Socio-ethical analysis of equity in access to nutrigenomics interventions for obesity prevention: a focus group study.
Omics : a journal of integrative biology 2008;12(4):273-8.
2008: Béatrice Godard; Vural Ozdemir
Nutrigenomics and personalized diet: from molecule to intervention and nutri-ethics.
Omics : a journal of integrative biology 2008;12(4):227-8.
2008: Lise Lévesque; Vural Ozdemir; Bart Gremmen; Béatrice Godard
Integrating anticipated nutrigenomics bioscience applications with ethical aspects.
Omics : a journal of integrative biology 2008;12(1):1-16.
2007: Eleni Aklillu; Werner Kalow; Laszlo Endrenyi; Patricia Harper; Jun Miura; Vural Ozdemir
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Pharmacogenetics and genomics 2007;17(11):989-93.
2007: Vural Ozdemir; M Mazen Jamal; Klara Osapay; Martin R Jadus; Zsuzsanna Sandor; Mehrtash Hashemzadeh; Sandor Szabo
Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: revisiting the "brain-gut axis" hypothesis in ulcer pathogenesis.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2007;55(6):315-20.
2007: Nathalie Egalité; Vural Ozdemir; Béatrice Godard
Pharmacogenomics research involving racial classification: qualitative research findings on researchers' views, perceptions and attitudes towards socioethical responsibilities.
Pharmacogenomics 2007;8(9):1115-26.
2007: Vural Ozdemir; Béatrice Godard
Evidence-based management of nutrigenomics expectations and ELSIs.
Pharmacogenomics 2007;8(8):1051-62.
2007: Christopher Reist; Vural Ozdemir; Eric Wang; Mehrtash Hashemzadeh; Steven Mee; Robert K Moyzis
Novelty seeking and the dopamine D4 receptor gene (DRD4) revisited in Asians: haplotype characterization and relevance of the 2-repeat allele.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2007;144B(4):453-7.
2007: Vural Ozdemir; Leif Bertilsson; Jun Miura; Erin Carpenter; Christopher Reist; Patricia Harper; Jolanta Widén; Jan-Olof Svensson; Lawrence J Albers; James L Kennedy; Laszlo Endrenyi; Werner Kalow
CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.
Pharmacogenetics and genomics 2007;17(5):339-47.
2007: Vural Ozdemir; Bryn Williams-Jones; Janice E Graham; Sheldon H Preskorn; Dimitrios Gripeos; Stephen J Glatt; Robert H Friis; Christopher Reist; Sandor Szabo; James B Lohr; Toshiyuki Someya
Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2007;55(3):130-41.
2007: Vural Ozdemir; Bryn Williams-Jones; Dan M Cooper; Toshiyuki Someya; Béatrice Godard
Mapping translational research in personalized therapeutics: from molecular markers to health policy.
Pharmacogenomics 2007;8(2):177-85.
2007: Christopher Reist; Jim Mintz; Lawrence J Albers; M Mazen Jamal; Sandor Szabo; Vural Ozdemir
Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002.
Journal of clinical psychopharmacology 2007;27(1):46-51.
2006: Vural Ozdemir; Arzu Gunes; Marja-Liisa Dahl; Maria Gabriella Scordo; Bryn Williams-Jones; Toshiyuki Someya
Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness?
Pharmacogenomics 2006;7(8):1199-210.
2006: Vural Ozdemir; Bryn Williams-Jones
Democracy unleashed--unpacking the tooth fairy in drug industry R&D.
Nature biotechnology 2006;24(11):1324-6; author reply 1326-7.
2006: Vural Ozdemir; Bryn Williams-Jones; Stephen J Glatt; Ming T Tsuang; James B Lohr; Christopher Reist
Shifting emphasis from pharmacogenomics to theragnostics.
Nature biotechnology 2006;24(8):942-6.
2006: Vural Ozdemir; Eleni Aklillu; Steven Mee; Leif Bertilsson; Lawrence J Albers; Janice E Graham; Michael Caligiuri; James B Lohr; Christopher Reist
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.
Expert opinion on pharmacotherapy 2006;7(2):119-33.
2005: Fatih Ozdener; Z Gülbas; K Erol; Vural Ozdemir
5-Hydroxytryptamine-2A receptor gene (HTR 2 A) candidate polymorphism (T 102 C): Role for human platelet function under pharmacological challenge ex vivo.
Methods and findings in experimental and clinical pharmacology 2005;27(6):395-400.
2005: Lawrence J Albers; Vural Ozdemir; Stephen R Marder; Maria Augusta Raggi; Manickam Aravagiri; Laszlo Endrenyi; Christopher Reist
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy.
Journal of clinical psychopharmacology 2005;25(2):170-4.
2004: Lawrence J Albers; Vural Ozdemir
Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.
Current medicinal chemistry 2004;11(3):297-312.
2003: Fatih Ozdener; Vural Ozdemir
Fasidotril Eli Lilly.
Current opinion in investigational drugs (London, England : 2000) 2003;4(9):1113-9.
2002: Mario Masellis; Vincenzo S Basile; Pierandrea Muglia; Vural Ozdemir; Fabio Macciardi; James L Kennedy
Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder.
Behavioural brain research 2002;130(1-2):85-90.
2002: Vural Ozdemir; Jeanne Fourie; Fatih Ozdener
Aripiprazole (Otsuka Pharmaceutical Co).
Current opinion in investigational drugs (London, England : 2000) 2002;3(1):113-20.
2001: Vural Ozdemir; Werner Kalow; Allan B Okey; Maria S M Lam; Lawrence J Albers; Christopher Reist; J Fourie; P Posner; E J Collins; R Roy
Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.
Journal of clinical psychopharmacology 2001;21(6):603-7.
2001: Vural Ozdemir; Werner Kalow; P Posner; E J Collins; James L Kennedy; Bing-Kou Tang; Lawrence J Albers; Christopher Reist; R Roy; W Walkes; P Afra
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Journal of clinical psychopharmacology 2001;21(4):398-407.
2001: Vincenzo S Basile; Vural Ozdemir; Mario Masellis; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Fabio Macciardi; Arturas Petronis; James L Kennedy
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
Molecular psychiatry 2001;6(2):230-4.
2001: Vural Ozdemir; Vincenzo S Basile; Mario Masellis; James L Kennedy
Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes.
Journal of biochemical and biophysical methods 2001;47(1-2):151-7.
2001: Werner Kalow; Vural Ozdemir; László Tóthfalusi
Multigenic traits and risk assessment in pharmacology: a population approach.
The pharmacogenomics journal 2001;1(4):234-6.
2001: Vural Ozdemir; Neil H Shear; Werner Kalow
What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?
Drug safety : an international journal of medical toxicology and drug experience 2001;24(2):75-85.
2000: Lawrence J Albers; Christopher Reist; RL Vu; K Fujimoto; Vural Ozdemir; Daiga M Helmeste; Russell Poland; Siu-Wa Tang
Effect of venlafaxine on imipramine metabolism.
Psychiatry research 2000;96(3):235-43.
2000: Vural Ozdemir; Werner Kalow; Bing-Kou Tang; A D Paterson; S E Walker; Laszlo Endrenyi; Angela D M Kashuba
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.
Pharmacogenetics 2000;10(5):373-88.
2000: Vincenzo S Basile; Vural Ozdemir; Mario Masellis; M L Walker; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Gustavo Alva; Werner Kalow; Fabio Macciardi; James L Kennedy
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.
Molecular psychiatry 2000;5(4):410-7.
2000: Mario Masellis; Vincenzo S Basile; Vural Ozdemir; Herbert Y Meltzer; Fabio Macciardi; James L Kennedy
Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine.
Biological psychiatry 2000;47(3):252-66.
1999: Werner Kalow; Vural Ozdemir; Bing-Kou Tang; László Tóthfalusi; Laszlo Endrenyi
The science of pharmacological variability: an essay.
Clinical pharmacology and therapeutics 1999;66(5):445-7.
1999: Vural Ozdemir; R F Tyndale; Kenton Reed; Nathan Herrmann; Edward M Sellers; Werner Kalow; Claudio A Naranjo
Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.
Journal of clinical psychopharmacology 1999;19(5):472-5.
1998: Vural Ozdemir; Claudio A Naranjo; RW Shulman; Nathan Herrmann; Edward M Sellers; Kenton Reed; Werner Kalow
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Journal of clinical psychopharmacology 1998;18(3):198-207.
1998: Vural Ozdemir; Claudio A Naranjo; Nathan Herrmann; RW Shulman; Edward M Sellers; Kenton Reed; Werner Kalow
The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.
Journal of clinical psychopharmacology 1998;18(1):55-61.
1997: Vural Ozdemir; Claudio A Naranjo; Nathan Herrmann; Kenton Reed; Edward M Sellers; Werner Kalow
Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.
Clinical pharmacology and therapeutics 1997;62(3):334-47.
1997: RW Shulman; Vural Ozdemir
Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
Canadian journal of psychiatry. Revue canadienne de psychiatrie 1997;42 Suppl 1():4S-9S.
1997: Claudio A Naranjo; RW Shulman; Vural Ozdemir
Development and evaluation of a clinical psychopharmacology educational curriculum.
Journal of clinical pharmacology 1997;37(6):474-9.
1996: Vural Ozdemir; J Fourie; Usoa E Busto; Claudio A Naranjo
Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?
Clinical pharmacokinetics 1996;31(5):372-85.
1994: Vural Ozdemir; Karen E Bremner; Claudio A Naranjo
Treatment of alcohol withdrawal syndrome.
Annals of medicine 1994;26(2):101-5.